Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18768689 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | July 2024 | March 2025 | Allow | 9 | 1 | 0 | No | No |
| 18762013 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | February 2025 | Allow | 8 | 2 | 0 | No | No |
| 18481951 | METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN | October 2023 | April 2024 | Allow | 6 | 2 | 0 | Yes | No |
| 18210693 | ECO-FRIENDLY HERBICIDES CONTAINING PELARGONIC ACID FOR FOLIAR FERTILZATION AND FOR BACTERICIDAL AND HARMFUL BIRD AND ANIMAL REPELLENT FUNCTIONS | June 2023 | March 2024 | Allow | 9 | 1 | 0 | No | No |
| 18208824 | ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASIS | June 2023 | January 2026 | Abandon | 31 | 0 | 1 | No | No |
| 18031942 | MICROSUSPENSION AGAINST PARASITES AND METHOD FOR OBTAINING SAME | April 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18295918 | LIPID NANOPARTICLES AND LIPOSOMES | April 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18167261 | INJECTABLE NEUROSTEROID FORMULATIONS CONTAINING NANOPARTICLES | February 2023 | January 2026 | Abandon | 36 | 1 | 1 | No | No |
| 18159747 | PROCESSES AND SYSTEMS FOR CATALYTIC MANUFACTURE OF WAX ESTER DERIVATIVES | January 2023 | December 2024 | Allow | 22 | 3 | 0 | No | No |
| 18098654 | RAPAMYCIN (RAPA) SELF-MICROEMULSIFYING INJECTION AND PREPARATION METHOD AND USE THEREOF | January 2023 | April 2025 | Allow | 27 | 3 | 0 | No | No |
| 18148707 | COSMETIC COMPOSITIONS WITH HIGH AMOUNTS OF LACTONE POLYOLS | December 2022 | June 2024 | Allow | 18 | 2 | 0 | No | No |
| 18068631 | TOFACITINIB EXTENDED RELEASE FORMULATIONS | December 2022 | November 2024 | Abandon | 23 | 2 | 0 | No | No |
| 18071809 | STABLE AGRICULTURAL COMPOSITIONS | November 2022 | August 2024 | Allow | 20 | 2 | 0 | No | No |
| 18056315 | IMPLANTABLE AND BIODEGRADABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | November 2022 | September 2025 | Allow | 34 | 4 | 1 | Yes | No |
| 17982556 | Implantable Device for Treating an Inflammatory Eye Condition | November 2022 | June 2025 | Abandon | 31 | 4 | 0 | No | No |
| 18050496 | COSMETIC COMPOSITION COMPRISING HIGH AMOUNTS OF CERAMIDE-NP | October 2022 | May 2024 | Allow | 19 | 2 | 0 | No | No |
| 17975968 | LIPID NANOPARTICLE WITH TARGET INTEGRIN FUNCTION AND USES THEREOF | October 2022 | January 2025 | Abandon | 27 | 2 | 1 | No | No |
| 18050223 | COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF HYDROXYPROPYL TETRAHYDROPYRANTRIOL | October 2022 | September 2025 | Allow | 35 | 3 | 0 | Yes | Yes |
| 17957744 | NEW STYLING COMPOSITION FOR PROVIDING VARIOUS ADVANTAGEOUS PROPERTIES TO THE HAIR | September 2022 | December 2024 | Allow | 26 | 4 | 0 | Yes | No |
| 17898897 | BIODEGRADABLE LUNG SEALANTS | August 2022 | July 2025 | Allow | 35 | 4 | 1 | Yes | No |
| 17895004 | THERAPEUTIC COMPOSITION DELIVERY DEVICE | August 2022 | September 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17904687 | USE OF COMPOSITION IN TREATING ATHEROSCLEROSIS | August 2022 | February 2026 | Allow | 41 | 2 | 0 | No | No |
| 17872830 | INHALABLE THERAPEUTICS | July 2022 | January 2025 | Allow | 30 | 3 | 1 | No | No |
| 17791977 | INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS | July 2022 | August 2025 | Allow | 37 | 1 | 1 | No | No |
| 17784155 | AMPHOTERICIN B CONJUGATED STABILIZED GOLD NANOPARTICLES AND USES THEREOF | June 2022 | October 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17773437 | MICROCAPSULE, PREPARATION METHOD AND APPLICATION THEREOF | April 2022 | August 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17753229 | MYO-INOSITOL AND THE PREVENTION OF PRETERM BIRTH | February 2022 | January 2026 | Allow | 47 | 3 | 0 | No | No |
| 17637278 | MODIFICATION OF PLANT MESSENGER PACKS WITH CHARGED LIPIDS | February 2022 | May 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17635116 | NANOPARTICLES FOR THE TREATMENT OF CANCER BY RADIOFREQUENCY RADIATION | February 2022 | December 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17583051 | NUTRACEUTICAL OR PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME OR OF DISEASES OR DISORDERS RELATED THERETO | January 2022 | June 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17625134 | NANO-DISPERSION METHODS FOR CANNABIS EXTRACT | January 2022 | October 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17554553 | METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN | December 2021 | December 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17617902 | CARRIER-BASED FORMULATIONS AND RELATED METHODS | December 2021 | February 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17595165 | MICROCAPSULE | November 2021 | May 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17610425 | NANOPARTICLE COMPLEX FOR TREATING DISEASES AND METHOD FOR MANUFACTURING THE SAME | November 2021 | April 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17609857 | KETONE BODIES ENCLOSED IN MICROBEADS | November 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17606417 | COMPOUND COMPRISING A FUNCTIONAL AGENT AND A WAXY MATRIX INCLUDING AN ORGANOSILICON MATERIAL, AND ASSOCIATED MANUFACTURING METHOD | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17605422 | THROMBOLYTIC AND NEURO/VASCULOPROTECTIVE NANOCONJUGATES | October 2021 | May 2025 | Allow | 43 | 2 | 0 | No | No |
| 17602239 | pH-RESPONSIVE SILICA METAL ORGANIC FRAMEWORK NANOPARTICLES FOR DELIVERY OF BIOACTIVE MOLECULES | October 2021 | May 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17601111 | HYDROPHILIC SILICA/POLYMER BLEND | October 2021 | November 2024 | Allow | 37 | 2 | 0 | No | No |
| 17601178 | Immunotherapeutic Nanoparticles And Methods Relating Thereto | October 2021 | March 2026 | Allow | 53 | 4 | 0 | No | No |
| 17491570 | GELATIN AND USES THEREOF | October 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17593982 | 'SMART' HYDROGEL FOR THE RADIOSENSITIZATION AND SUSTAINED DELIVERY OF THERAPEUTICS TRIGGERED BY IRRADIATION | September 2021 | September 2025 | Allow | 48 | 2 | 0 | No | No |
| 17439617 | SOLID LIPID NANOPARTICLES OF CURCUMIN | September 2021 | November 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17434883 | NANOPARTICLE COMPOSITION WITH REDUCED CONTAMINANT AND PRODUCTION METHOD THEREOF | August 2021 | February 2025 | Allow | 41 | 2 | 0 | Yes | No |
| 17434297 | NANOPARTICLE MEDIATED THERAPY | August 2021 | December 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17432877 | CARNIVOROUS WASP CONTROL AGENT | August 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17432308 | HERBICIDAL COMPOUNDS | August 2021 | July 2024 | Allow | 35 | 1 | 0 | No | No |
| 17430931 | Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps | August 2021 | February 2025 | Abandon | 42 | 1 | 0 | Yes | No |
| 17310586 | SYSTEM AND METHOD FOR FABRICATION OF LARGE, POROUS DRUG-ELUTING SILK MATERIALS USING CRYOGRANULATION | August 2021 | October 2025 | Abandon | 50 | 2 | 0 | Yes | Yes |
| 17429193 | CINNOLINIUM COMPOUNDS FOR USE IN A METHOD OF CONTROLLING UNWANTED PLANT GROWTH | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17423600 | STABLE SOLID DISPERSION OF A B-RAF KINASE DIMER INHIBITOR, METHODS OF PREPARATION, AND USES THEREFOR | July 2021 | October 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17421826 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DIABETIC CATARACT | July 2021 | August 2025 | Allow | 49 | 3 | 0 | No | No |
| 17421116 | STABILIZED NON-ENVELOPED VIRUS COMPOSITIONS | July 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17369609 | Resurrection Of Antibiotics That MRSA Resists By Silver-Doped Bioactive Glass-Ceramic Particles | July 2021 | February 2026 | Abandon | 55 | 1 | 1 | No | No |
| 17417612 | GINGSENG-BASED COSMETIC COMPOSITION | June 2021 | March 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17312848 | METHOD FOR ENHANCING THE GROWTH AND SURVIVAL RATE OF MICROORGANISMS | June 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17312828 | CONJUGATES AND NANOPARTICLES OF HYALURONIC ACID AND EPIGALLOCATECHIN-3-O-GALLATE AND USES THEREOF | June 2021 | April 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17312646 | COMPOSITION COMPRISING A MODIFIED PHOTO-DIMERIZABLE POLYMER AND AN ALKALINE AGENT AND/OR AN AMINO ALKOXYSILANE DERIVATIVE AND TREATMENT METHOD IMPLEMENTING THE COMPOSITION | June 2021 | February 2026 | Abandon | 56 | 3 | 1 | No | No |
| 17296349 | SILICA MODIFIED VATERITE JANUS DRUG DELIVERY PARTICLES | May 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17295610 | DRY POWDER INHALATION FORMULATION AND ITS USE FOR THE THERAPEUTIC TREATMENT OF LUNGS | May 2021 | January 2025 | Allow | 44 | 3 | 0 | No | No |
| 17294367 | DEUTERATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | May 2021 | March 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17291942 | LIPID NANOPARTICLE FORMULATIONS | May 2021 | January 2025 | Allow | 45 | 2 | 0 | No | No |
| 17291246 | NANOPARTICLE STRUCTURE AND METHOD OF FORMING THE SAME | May 2021 | August 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17289496 | COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES WITH SYNTHETIC AUXIN HERBICIDES OR AUXIN TRANSPORT INHIBITORS | April 2021 | November 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 17237201 | PHARMACEUTICAL FORMULATIONS | April 2021 | August 2025 | Allow | 52 | 4 | 1 | Yes | No |
| 17287590 | INORGANIC POWDER COMPOSITE, METHOD FOR PRODUCING SAME, WATER-IN-OIL EMULSION COMPOSITION, AND SUNSCREEN COSMETIC | April 2021 | August 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17229829 | Magneto-Patterned-Cell-Laden Hydrogel Materials and Methods of Making and Using Same | April 2021 | July 2024 | Allow | 39 | 2 | 1 | No | No |
| 17278839 | WATER-DISPERSIBLE FINE PARTICLE | March 2021 | April 2024 | Allow | 37 | 1 | 0 | No | No |
| 17276409 | PLANT PATHOGEN CONTROL AGENT | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17274215 | METHOD OF MAKING A BIOCOMPATIBLE MICRO-SWIMMER AND METHOD OF USING SUCH A MICRO-SWIMMER | March 2021 | October 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17271486 | POLYMER MICRONEEDLE MEDIATED DRUG DELIVERY | February 2021 | September 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17270342 | NANOSTRUCTURED NANOPARTICLES COMPRISING ONE OR MORE ACTIVE INGREDIENTS FOR THE TREATMENT OF DISEASES CAUSED BY TRYPANOSOMES AND FOR THE TREATMENT OF TUMOURS OF NEURAL ORIGIN, COMPOSITIONS COMPRISING SAME, A PREPARATION METHOD AND THERAPEUTIC USE THEREOF | February 2021 | April 2025 | Abandon | 50 | 3 | 0 | No | No |
| 17265554 | BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES | February 2021 | November 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16886060 | COMPOSITION FOR IMPREGNATING A SUBSTRATE, IN PARTICULAR A WATCHSTRAP | May 2020 | January 2025 | Abandon | 56 | 4 | 0 | Yes | No |
| 16392475 | FORMULATIONS OF CREATINE AND CYCLODEXTRIN EXHIBITING IMPROVED BIOAVAILABILITY | April 2019 | December 2024 | Allow | 60 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ATKINSON, JOSHUA ALEXANDER.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ATKINSON, JOSHUA ALEXANDER works in Art Unit 1612 and has examined 45 patent applications in our dataset. With an allowance rate of 46.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner ATKINSON, JOSHUA ALEXANDER's allowance rate of 46.7% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ATKINSON, JOSHUA ALEXANDER receive 1.71 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ATKINSON, JOSHUA ALEXANDER is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +42.5% benefit to allowance rate for applications examined by ATKINSON, JOSHUA ALEXANDER. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 35.7% of applications are subsequently allowed. This success rate is in the 80% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
When applicants file petitions regarding this examiner's actions, 133.3% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.